Literature DB >> 21472230

Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma.

Viviana E Laurent1, Laura L Otero, Valeria Vazquez, Sandra Camarero, Mariano R Gabri, María Labraga, María T G De Dávila, Guillermo L Chantada, Daniel F Alonso.   

Abstract

Extraocular dissemination is the main cause of death in patients with retinoblastoma (RB) in developing countries, and there are few molecular markers that are useful for the evaluation of minimal disseminated disease. The GD2 ganglioside is known to be expressed by RB cells that metastasize in bone marrow, and the activity of the enzyme responsible for its synthesis, GD2 synthase, can be detected in neuroblastoma, which shares many phenotypic features with RB. The purpose of the present study was to optimize the detection of GD2 synthase expression by reverse transcription-polymerase chain reaction (RT-PCR) followed by nested-PCR in human RB cell lines and patient samples. The optimization strategy was carried out using the RB cell lines Y79 and WERI-Rb1 and specific primers designed for the human sequence of GD2 synthase mRNA. We detected GD2 synthase expression with at least 200 and 40 pg of total RNA extracted from cultured RB cells using a first round of RT-PCR amplification or a second round of nested-PCR, respectively. We also confirmed the expression of GD2 synthase by RT-PCR and immunohistochemical detection of the ganglioside in human RB tumors xenotransplanted in nude mice. Using tumor bank specimens from eight RB patients, we were able to demonstrate the presence of GD2 synthase mRNA in blood and cerebrospinal fluid samples in cases of extraocular dissemination of the tumor. The sequence was not detected in samples derived from children with low-risk disease or healthy adult volunteers. Hence, GD2 synthase mRNA detection through an optimized nested RT-PCR assay is a promising tool for the assessment of minimal disseminated disease in enucleated patients.

Entities:  

Year:  2010        PMID: 21472230     DOI: 10.3892/mmr_00000248

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  11 in total

Review 1.  Retinoblastoma, the visible CNS tumor: A review.

Authors:  Helen Dimaras; Timothy W Corson
Journal:  J Neurosci Res       Date:  2018-01-03       Impact factor: 4.164

Review 2.  The bone marrow metastasis niche in retinoblastoma.

Authors:  Abbas Khosravi; Saeid Shahrabi; Mohammad Shahjahani; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-06-11       Impact factor: 6.730

3.  Does GD2 synthase (GD2S) detect cancer stem cells in blood samples of breast carcinomas?

Authors:  Maryam Mansoori; Isa Abdi Rad; Alireza Mirzaei; Kevin J Tam; Seyed Mohsen Hosseini; Rahim Mahmodlu; Fatemeh Mansouri; Leili Saeednejad Zanjani; Zahra Madjd
Journal:  J Appl Biomed       Date:  2021-09-16       Impact factor: 1.797

4.  GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision.

Authors:  Kai Wang; Yuhui Chen; Sarah Ahn; Min Zheng; Elisa Landoni; Gianpietro Dotti; Barbara Savoldo; Zongchao Han
Journal:  Nat Cancer       Date:  2020-10-12

Review 5.  Retinoblastoma genetics in India: From research to implementation.

Authors:  Helen Dimaras
Journal:  Indian J Ophthalmol       Date:  2015-03       Impact factor: 1.848

6.  Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells.

Authors:  Nicola Mitwasi; Anja Feldmann; Ralf Bergmann; Nicole Berndt; Claudia Arndt; Stefanie Koristka; Alexandra Kegler; Justyna Jureczek; Anja Hoffmann; Armin Ehninger; Marc Cartellieri; Susann Albert; Claudia Rossig; Gerhard Ehninger; Jens Pietzsch; Jörg Steinbach; Michael Bachmann
Journal:  Oncotarget       Date:  2017-09-18

7.  Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway.

Authors:  Huixue Wang; Jie Yang; Hui Pan; Mei Chee Tai; Mohamed H Maher; Renbing Jia; Shengfang Ge; Linna Lu
Journal:  Onco Targets Ther       Date:  2020-05-08       Impact factor: 4.147

8.  Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2.

Authors:  Jan Müller; Robin Reichel; Sebastian Vogt; Stefan P Müller; Wolfgang Sauerwein; Wolfgang Brandau; Angelika Eggert; Alexander Schramm
Journal:  PLoS One       Date:  2016-10-07       Impact factor: 3.240

9.  CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.

Authors:  Lena Andersch; Josefine Radke; Anika Klaus; Silke Schwiebert; Annika Winkler; Elisa Schumann; Laura Grunewald; Felix Zirngibl; Carina Flemmig; Michael C Jensen; Claudia Rossig; Antonia Joussen; Anton Henssen; Angelika Eggert; Johannes H Schulte; Annette Künkele
Journal:  BMC Cancer       Date:  2019-09-09       Impact factor: 4.430

10.  Upregulation of Ganglioside GD2 Synthase (GD2S), as a New Putative Cancer Stem Cell Marker in Breast Carcinomas.

Authors:  Maryam Mansoori; Alireza Mirzaei; Isa Abdi Rad; Rahim Mahmodlou; Fatemeh Mansouri; Leili Saeednejad Zanjani; Zeynab Asadi-Lari; Zahra Madjd
Journal:  Med J Islam Repub Iran       Date:  2021-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.